Stock: BABA
Consensus EPS: $1.97
ROE: 14.8%
P/E: 25.6
P/FCF: 23.9
P/B: 3.5
Current Ratio: 1.7
P/S: 4.8
PEG: 1.2
RSI: 38.6
SMA20: -5.9% SMA50: -9.4% SMA200: -16.8%
Basic Information: BABA is the ticker symbol for Alibaba Group Holding Ltd, a Chinese e-commerce giant that operates various online platforms and cloud computing services. The company is one of the largest and most diversified internet companies in the world, with segments such as core commerce, cloud computing, digital media and entertainment, innovation initiatives, and others. The company’s main revenue sources are commissions from online transactions, fees from online marketing services, subscription fees from cloud computing services, and membership fees from various platforms.
Technical analysis: BABA has been in a downtrend since October 2020, when it reached an all-time high of $319.32. The stock has been under pressure from regulatory uncertainties in China, as well as increased competition from rivals such as JD.com and Pinduoduo. The stock recently broke below its support level of $200, which was also the lower boundary of a descending triangle pattern. The stock is now trading below its 20-day, 50-day, and 200-day moving averages, indicating a bearish momentum. The RSI is below 40, suggesting that the stock is oversold and may be due for a bounce. However, the MACD is below zero and declining, indicating that the selling pressure is still strong.
Fundamental analysis: BABA has a strong financial position, with a high return on equity of 14.8%, which is above the industry average of 11%. The company also has a solid free cash flow margin of 18.9%, which allows it to invest in growth opportunities and reward shareholders with dividends and buybacks. The company’s earnings growth has been impressive, with a five-year average of 29%, which is well above the industry average of 17%. The company’s revenue growth has also been robust, with a five-year average of 43%, which is also higher than the industry average of 25%. The company’s valuation is reasonable, with a forward P/E of 25.6, which is lower than the industry average of 31.4. The company’s PEG ratio of 1.2 also indicates that the stock is fairly priced relative to its expected growth rate.
Outlook: BABA is expected to report its fiscal first-quarter earnings on August 10th, before the market opens. The consensus estimate is for earnings of $1.97 per share on revenue of $32.29 billion, representing year-over-year growth of 12% and 14%, respectively. The company has a history of beating earnings estimates in the past four quarters, with an average surprise of 23%. However, the company faces some headwinds in the near term, such as regulatory scrutiny from the Chinese government, which recently fined BABA $2.8 billion for antitrust violations and ordered it to overhaul its business practices. The company also faces increased competition from domestic and international rivals in the e-commerce and cloud computing markets.
Verdict:
Based on the technical and fundamental analysis above, I would say that BABA is most likely to exceed expectation in terms of earnings per share, but may still face some challenges in terms of revenue growth and market sentiment. The stock may experience some volatility around the earnings date, as investors weigh the pros and cons of investing in BABA amid the uncertain regulatory environment in China. Therefore, I would advise caution and patience for long-term investors who believe in BABA’s growth potential and competitive advantages.
Stock: IONQ
Consensus EPS: -$0.13
Basic Information: IONQ is the ticker symbol for IonQ Inc., a quantum computing company that develops and operates quantum computers based on trapped ions. The company claims to have the world’s most powerful quantum computers, which can run a variety of applications such as optimization, machine learning, simulation, and cryptography. The company also offers cloud access to its quantum computers through platforms such as Amazon Web Services and Microsoft Azure. The company went public in July 2021 through a merger with a special purpose acquisition company (SPAC) called dMY Technology Group III.
Technical analysis: IONQ has a very limited trading history, as it only started trading on the Nasdaq on July 2nd, 2021. The stock opened at $11.75 and reached a high of $12.50 on the same day, but then declined to a low of $7.85 on July 19th. The stock has since recovered some of its losses and is currently trading around $9.50. The stock is below its 20-day moving average of $9.80, indicating a bearish trend. The RSI is around 45, suggesting that the stock is neither overbought nor oversold. The MACD is below zero and rising, indicating that the selling pressure is easing and a possible bullish crossover may occur.
Fundamental analysis: IONQ has not yet reported any financial results as a public company, so there is no data available for metrics such as revenue, earnings, cash flow, or profitability. However, the company has provided some projections for its future performance, based on its business plan and growth strategy. The company expects to generate revenue of $4.1 million in 2021, $18.8 million in 2022, and $77 million in 2023, representing compound annual growth rates of 150% and 108%, respectively. The company also expects to achieve positive gross margin by 2022 and positive EBITDA by 2025. The company’s valuation is based on its potential to capture a significant share of the emerging quantum computing market, which is expected to grow from $472 million in 2021 to $65 billion by 2030, according to the company’s estimates.
Outlook: IONQ is expected to report its second-quarter earnings on August 10th, after the market closes. The consensus estimate is for a loss of $0.13 per share on revenue of $4.1 million, representing year-over-year growth of N/A and N/A, respectively. This will be the first earnings report for IONQ as a public company, so there is no historical data to compare with. However, the company may provide some updates on its product development, customer acquisition, and strategic partnerships in the quantum computing space.
Verdict:
Based on the technical and fundamental analysis above, I would say that IONQ is most likely to hit expectation in terms of earnings per share and revenue, as the company has already provided guidance for its second-quarter performance. However, the stock may still face some uncertainty and volatility in the near term, as investors evaluate the company’s growth prospects and competitive position in the nascent quantum computing market. Therefore, I would advise caution and research for investors who are interested in this high-risk high-reward opportunity in the cutting-edge field of quantum computing.
Stock: ZYME (Zymeworks Inc)
Consensus EPS: -$0.51
ROE: -28.9%
P/B: 3.8
Current Ratio: 5.7
P/S: 11.9
RSI: 40.2
SMA20: $7.70 SMA50: $8.24 SMA200: $8.12
Basic Information: Zymeworks Inc is a Canada-based biotechnology company that develops and commercializes novel therapeutics for the treatment of cancer and other diseases. The company’s pipeline includes bispecific antibodies, antibody-drug conjugates, cytokine derivatives, and cell therapies.
Technical analysis: ZYME is trading below its 20, 50, and 200-day moving averages, indicating a bearish trend. The stock has been in a downtrend since February 2021, when it reached a high of $14.75. The stock has recently bounced from its support level of $7.00, which was also the low in December 2020. The RSI is near 40, suggesting that the stock is oversold and may be due for a rebound.
Fundamental analysis: ZYME reported a loss of $0.37 per share in the first quarter, beating the consensus estimate of a loss of $0.64 per share. The company also posted revenues of $35.58 million, surpassing the consensus estimate by 1.52%. The company has several clinical trials ongoing or planned for its lead candidates, such as zanidatamab and ZW491. The company also has collaborations with major pharmaceutical companies such as Eli Lilly, Merck, GlaxoSmithKline, and BeiGene2.
Outlook: ZYME is a speculative play in the biotechnology sector, with a high risk-reward profile. The stock has a high growth potential if its pipeline products succeed in clinical trials and regulatory approvals, but also faces significant uncertainties and challenges in terms of competition, safety, efficacy, and profitability.
Verdict: ZYME is a hold for long-term investors who are willing to take on high risk for high reward in the biotechnology sector. The stock has a promising pipeline and partnerships, but also requires patience and tolerance for volatility.
Stock: INDI (indie Semiconductor Inc)
Consensus EPS: -$0.09
ROE: -25%
Basic Information: indie Semiconductor Inc is a US-based company that designs and manufactures semiconductor solutions for automotive applications such as advanced driver assistance systems (ADAS), connectivity, user experience, and electrification. The company also offers cloud-based software and artificial intelligence solutions for its products. The company went public in June 2021 through a merger with a special purpose acquisition company (SPAC) called Thunder Bridge Acquisition II.
Technical analysis: INDI has a very limited trading history, as it only started trading on the Nasdaq on June 10th, 2021. The stock opened at $10.00 and reached a high of $11.12 on the same day, but then declined to a low of $5.66 on July 19th. The stock has since recovered some of its losses and is currently trading around $8.50. The stock is below its 20-day moving average of $8.80, indicating a bearish trend. The RSI is near 50, suggesting that the stock is neither overbought nor oversold.
Fundamental analysis: INDI has not yet reported any financial results as a public company, so there is no data available for metrics such as revenue, earnings, cash flow, or profitability. However, the company has provided some projections for its future performance, based on its business plan and growth strategy. The company expects to generate revenue of $40.45 million in 2021, $88.6 million in 2022, and $176 million in 2023, representing compound annual growth rates of 120% and 50%, respectively. The company also expects to achieve positive gross margin by 2022 and positive EBITDA by 2024. The company’s valuation is based on its potential to capture a significant share of the growing automotive semiconductor market, which is expected to grow from $37 billion in 2020 to $67 billion by 2025, according to the company’s estimates.
Outlook: INDI is a high-growth play in the automotive semiconductor sector, with a high risk-reward profile. The stock has a high growth potential if its products gain traction and adoption in the automotive industry, especially in the areas of ADAS, connectivity, and electrification. However, the stock also faces significant uncertainties and challenges in terms of competition, regulation, innovation, and execution.
Verdict: INDI is a buy for long-term investors who are looking for exposure to the automotive semiconductor sector. The stock has a strong growth potential and a differentiated product portfolio that offers high performance, integration, and customization. However, investors should also be aware of the risks and volatility involved in investing in a newly public company with no proven track record or profitability.
Comments